Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
NRIX Stock — Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. (NRIX)
Updated October 16, 2026.
NRIX is a Stock. Total return is 28.5% over the past 6.2 years, 130.4 points behind SPY at 158.9%.
Nurix Therapeutics is a clinical-stage biopharmaceutical company developing small molecule and antibody therapies for cancer, inflammatory conditions, and other diseases, with drug candidates in Phase 1 and Phase 2 trials and strategic collaborations with Gilead Sciences, Sanofi, and Pfizer. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to early-stage biotech development rather than current income.
NRIX performance versus SPY
Price and return data through 2026-10-16.
Total return is 28.5% over the past 6.2 years, 130.4 points behind SPY at 158.9%. Over the past year its total return — price change plus distributions reinvested — is 143.5%. Its deepest 1-year drawdown was 32.8%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -2.9% | — |
| 3M | 5.9% | — |
| 6M | 46.3% | — |
| YTD | 28.7% | — |
| 1Y | 143.5% | — |
| 2Y CAGR | — | -2.70% |
| 3Y CAGR | — | 56.20% |
| 5Y CAGR | — | -3.30% |
| Since inception (6.2 years) | 28.5% | 4.10% |
NRIX key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 07/24/2020
- Distribution frequency
- None
- Last close
- $24.42 (as of 2026-10-16)
- Market cap
- $2,667,880,458
- Average volume
- 3692168.0
- Beta
- 1.821
- Payout ratio
- 0.0%
- P/E ratio
- 10.05
- EPS
- $2.43
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
NRIX risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 32.8%.
Who may consider NRIX — and who may not
It is a weaker fit for investors who need monthly cash flow (NRIX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on NRIX
Frequently asked questions
Does NRIX pay monthly?
No. NRIX does not currently distribute.
When does NRIX pay a dividend?
NRIX does not currently distribute.
How has NRIX performed?
Total return is 28.5% over the past 6.2 years, 130.4 points behind SPY at 158.9%. Over the past year its total return — price change plus distributions reinvested — is 143.5%. Its deepest 1-year drawdown was 32.8%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.